Cargando…

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes

BACKGROUND: Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor. The goal of this study was to determine the relationship of serum osteoprotegerin with vascular calcification in patients with type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Atsushi, Murata, Miho, Asano, Tomoko, Ikoma, Aki, Sasaki, Masami, Saito, Tomoyuki, Otani, Taeko, Jinbo, Sachimi, Ikeda, Nahoko, Kawakami, Masanobu, Ishikawa, San-e
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558393/
https://www.ncbi.nlm.nih.gov/pubmed/23302066
http://dx.doi.org/10.1186/1475-2840-12-11
_version_ 1782257425735221248
author Aoki, Atsushi
Murata, Miho
Asano, Tomoko
Ikoma, Aki
Sasaki, Masami
Saito, Tomoyuki
Otani, Taeko
Jinbo, Sachimi
Ikeda, Nahoko
Kawakami, Masanobu
Ishikawa, San-e
author_facet Aoki, Atsushi
Murata, Miho
Asano, Tomoko
Ikoma, Aki
Sasaki, Masami
Saito, Tomoyuki
Otani, Taeko
Jinbo, Sachimi
Ikeda, Nahoko
Kawakami, Masanobu
Ishikawa, San-e
author_sort Aoki, Atsushi
collection PubMed
description BACKGROUND: Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor. The goal of this study was to determine the relationship of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. METHODS: The subjects were 124 patients with type 2 diabetes mellitus, including 88 males and 36 females with a mean (± SD) age of 65.6 ± 8.2 years old. Serum levels of osteoprotegerin, osteocalcin, fibroblast growth factor 23 (FGF23), 25-hydroxyvitamin D3 and adiponectin were measured by ELISA. Vascular calcification in the cervical artery was examined by ultrasound sonography. The subjects were divided into 4 quartiles depending on serum osteoprotegerin levels. RESULTS: Vascular calcification was significantly higher in the 4th quartile and significantly lower in the 1st quartile of serum osteoprotegerin levels, compared to other quartiles. There were no differences in serum osteoprotegerin and vascular calcification among patients with different stages of diabetic nephropathy, but serum FGF23 levels were elevated in those with stage 4 diabetic nephropathy. Simple regression analysis showed that serum osteoprotegerin levels had significant positive correlations with age, systolic blood pressure and serum adiponectin levels, and significant negative correlations with BMI and serum 25-hydroxyvitamin D3. CONCLUSIONS: These findings suggest that elevated serum osteoprotegerin may be involved in vascular calcification independently of progression of diabetic nephropathy in patients with type 2 diabetes.
format Online
Article
Text
id pubmed-3558393
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35583932013-01-31 Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes Aoki, Atsushi Murata, Miho Asano, Tomoko Ikoma, Aki Sasaki, Masami Saito, Tomoyuki Otani, Taeko Jinbo, Sachimi Ikeda, Nahoko Kawakami, Masanobu Ishikawa, San-e Cardiovasc Diabetol Original Investigation BACKGROUND: Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor. The goal of this study was to determine the relationship of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. METHODS: The subjects were 124 patients with type 2 diabetes mellitus, including 88 males and 36 females with a mean (± SD) age of 65.6 ± 8.2 years old. Serum levels of osteoprotegerin, osteocalcin, fibroblast growth factor 23 (FGF23), 25-hydroxyvitamin D3 and adiponectin were measured by ELISA. Vascular calcification in the cervical artery was examined by ultrasound sonography. The subjects were divided into 4 quartiles depending on serum osteoprotegerin levels. RESULTS: Vascular calcification was significantly higher in the 4th quartile and significantly lower in the 1st quartile of serum osteoprotegerin levels, compared to other quartiles. There were no differences in serum osteoprotegerin and vascular calcification among patients with different stages of diabetic nephropathy, but serum FGF23 levels were elevated in those with stage 4 diabetic nephropathy. Simple regression analysis showed that serum osteoprotegerin levels had significant positive correlations with age, systolic blood pressure and serum adiponectin levels, and significant negative correlations with BMI and serum 25-hydroxyvitamin D3. CONCLUSIONS: These findings suggest that elevated serum osteoprotegerin may be involved in vascular calcification independently of progression of diabetic nephropathy in patients with type 2 diabetes. BioMed Central 2013-01-09 /pmc/articles/PMC3558393/ /pubmed/23302066 http://dx.doi.org/10.1186/1475-2840-12-11 Text en Copyright ©2013 Aoki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Aoki, Atsushi
Murata, Miho
Asano, Tomoko
Ikoma, Aki
Sasaki, Masami
Saito, Tomoyuki
Otani, Taeko
Jinbo, Sachimi
Ikeda, Nahoko
Kawakami, Masanobu
Ishikawa, San-e
Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title_full Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title_fullStr Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title_full_unstemmed Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title_short Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
title_sort association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558393/
https://www.ncbi.nlm.nih.gov/pubmed/23302066
http://dx.doi.org/10.1186/1475-2840-12-11
work_keys_str_mv AT aokiatsushi associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT muratamiho associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT asanotomoko associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT ikomaaki associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT sasakimasami associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT saitotomoyuki associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT otanitaeko associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT jinbosachimi associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT ikedanahoko associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT kawakamimasanobu associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes
AT ishikawasane associationofserumosteoprotegerinwithvascularcalcificationinpatientswithtype2diabetes